Medicus Pharma Submits Study Protocol to FDA

Medicus Pharma has submitted an optimized Phase 2 study protocol to the U.S. FDA for its drug Teverelix, targeting acute urinary retention. The study design emphasizes capital efficiency and accelerated development, aiming for near-term value creation. This strategic approach addresses a potential market of $2 billion, positioning Medicus Pharma for rapid progress and potential market entry if the trial proves successful.